BRPI0413313A - processos de secagem por atomização para formação de dispersões sólidas amorfas de medicamentos e polìmeros - Google Patents

processos de secagem por atomização para formação de dispersões sólidas amorfas de medicamentos e polìmeros

Info

Publication number
BRPI0413313A
BRPI0413313A BRPI0413313-7A BRPI0413313A BRPI0413313A BR PI0413313 A BRPI0413313 A BR PI0413313A BR PI0413313 A BRPI0413313 A BR PI0413313A BR PI0413313 A BRPI0413313 A BR PI0413313A
Authority
BR
Brazil
Prior art keywords
polymers
drying processes
spray drying
amorphous solid
medicaments
Prior art date
Application number
BRPI0413313-7A
Other languages
English (en)
Inventor
Ronald Arthur Beyerinck
Daniel Elmont Dobry
Dwayne Thomas Friesen
Dana Marie Settell
Roderick Jack Ray
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413313A publication Critical patent/BRPI0413313A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Glanulating (AREA)

Abstract

"PROCESSOS DE SECAGEM POR ATOMIZAçãO PARA FORMAçãO DE DISPERSõES SóLIDAS AMORFAS DE MEDICAMENTOS E POLìMEROS". Os processos de secagem por atomização são utilizados para formar composições farmacêuticas compreendendo uma dispersão sólida amorfa de um medicamento e de um polímero.
BRPI0413313-7A 2003-08-04 2004-07-27 processos de secagem por atomização para formação de dispersões sólidas amorfas de medicamentos e polìmeros BRPI0413313A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49240703P 2003-08-04 2003-08-04
US56898904P 2004-05-07 2004-05-07
PCT/IB2004/002519 WO2005011636A2 (en) 2003-08-04 2004-07-27 Spray drying processes for forming solid amorphous dispersions of drugs and polymers

Publications (1)

Publication Number Publication Date
BRPI0413313A true BRPI0413313A (pt) 2006-10-10

Family

ID=34118937

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413313-7A BRPI0413313A (pt) 2003-08-04 2004-07-27 processos de secagem por atomização para formação de dispersões sólidas amorfas de medicamentos e polìmeros

Country Status (18)

Country Link
US (1) US10383941B2 (pt)
EP (2) EP1653928B1 (pt)
JP (2) JP2007501219A (pt)
KR (1) KR20060087501A (pt)
AR (1) AR045188A1 (pt)
AT (1) ATE548027T1 (pt)
AU (1) AU2004261061A1 (pt)
BR (1) BRPI0413313A (pt)
CA (1) CA2534129A1 (pt)
CL (1) CL2004001884A1 (pt)
IL (1) IL173130A0 (pt)
MX (1) MXPA06001418A (pt)
NO (1) NO20060305L (pt)
NZ (1) NZ544892A (pt)
PT (1) PT1653928E (pt)
RU (1) RU2318495C2 (pt)
TW (1) TWI290852B (pt)
WO (1) WO2005011636A2 (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2007007148A1 (en) * 2005-07-14 2007-01-18 Pfizer Products Inc. Process for forming amorphous azithromycin particles
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
PT1926476E (pt) * 2005-08-29 2013-07-10 Sanofi Aventis Us Llc Dispersões sólidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3- fenil-3,5-di-hidro-4h-piridazino[4,5-b]indole-1-acetamida
GB0518769D0 (en) * 2005-09-14 2005-10-19 Medpharm Ltd Topical formulations
US7524442B2 (en) * 2006-01-10 2009-04-28 Nanomist Systems, Llc Method and device for manufacturing extremely fine particles and porous materials by controlled low temperature drying
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008032327A2 (en) * 2006-09-14 2008-03-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Organic nanoparticles obtained from microemulsions by solvent evaporation
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
PT103661B (pt) * 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US8916135B2 (en) * 2007-08-22 2014-12-23 Colorado School Of Mines Lanthanide nanoparticle conjugates and uses thereof
US20100284912A1 (en) * 2007-12-04 2010-11-11 Bracco Diagnostics Inc. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
WO2009085766A2 (en) * 2007-12-19 2009-07-09 Mutual Pharmaceutical Company, Inc. Fenofibric acid amorphous dispersion; method of making; and method of use thereof
WO2010017918A2 (de) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Amorphes ambrisentan
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
PT104350A (pt) * 2009-01-23 2010-07-23 Hovione Farmaci Ncia S A Processo de isolamento de tigeciclina
DE102009013611A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
CN101602764B (zh) * 2009-03-27 2011-06-29 浙江车头制药有限公司 一种阿昔洛韦2/3水合物的制备方法
US8968563B2 (en) * 2009-03-31 2015-03-03 Shimadzu Corporation Fractionating and refining device
CA2738573C (en) * 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
US20120076838A1 (en) * 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
RU2403049C1 (ru) * 2009-06-04 2010-11-10 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава) Способ получения таблеток эритромицина
US9364485B2 (en) 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US20110201076A1 (en) 2010-01-22 2011-08-18 Colorado School Of Mines Harvesting micro algae
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
WO2011154014A1 (en) * 2010-06-11 2011-12-15 Gea Process Engineering A/S Controlled humidity drying
US20130093111A1 (en) * 2010-06-14 2013-04-18 Xspray Microparticles Ab Apparatus and Method for the Production of Particles
JP5728174B2 (ja) * 2010-06-29 2015-06-03 藤崎電機株式会社 循環式の噴霧乾燥装置
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
WO2012014923A1 (ja) * 2010-07-29 2012-02-02 田辺工業株式会社 減圧噴霧乾燥方法及び減圧噴霧乾燥装置
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
RU2456065C2 (ru) * 2010-10-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Тамбовский государственный технический университет" ГОУ ВПО ТГТУ Способ микродозирования наноструктурных материалов
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP5522577B2 (ja) 2011-08-08 2014-06-18 ヤマトミシン製造株式会社 縫目のほつれ止め装置付二重環縫いミシン
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
BR112014032017A2 (pt) * 2012-07-17 2017-06-27 Dow Global Technologies Llc dispersão sólida, dispersão sólida extrudada e processo para produzir uma dispersão sólida
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
US9597339B2 (en) 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
RU2523520C1 (ru) * 2013-04-23 2014-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Тамбовский государственный технический университет" ФГБОУ ВПО ТГТУ Способ энергосберегающей сушки гранулированных полимерных материалов
EP3071037A4 (en) * 2013-11-22 2017-08-02 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
ES2857602T3 (es) * 2014-03-11 2021-09-29 Promius Pharma Llc Composiciones tópicas de corticosteroides
EP3140284A1 (en) * 2014-05-09 2017-03-15 AbbVie Inc. Crystal forms
AU2015292212B2 (en) 2014-07-25 2019-03-14 Laurent Pharmaceuticals Solid oral formulation of fenretinide
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
BR112018072113A2 (pt) * 2016-04-29 2019-02-12 Rousselot B.V. excipiente à base de proteínas para ingredientes farmacêuticos ativos
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
JP2019532068A (ja) * 2016-10-13 2019-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ 噴霧乾燥組成物の製造方法及び噴霧乾燥装置
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
JP6937016B2 (ja) * 2017-09-06 2021-09-22 東京理化器械株式会社 噴霧乾燥装置
CN107381691A (zh) * 2017-09-12 2017-11-24 哈尔滨锅炉厂环保工程技术有限公司 一种用于湿法烟气脱硫废水蒸发的蒸发炉
WO2019108029A1 (ko) * 2017-11-30 2019-06-06 주식회사 지투지바이오 도네페질을 함유하는 서방성 주사제제 및 그 제조방법
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
PT110585B (pt) 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
WO2020001713A1 (en) * 2018-06-29 2020-01-02 Gea Process Engineering A/S Gas disperser for guiding gas into a chamber, spray drying apparatus comprising such a gas disperser, and method of aligning a stream of gas in a gas disperser
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
MY210034A (en) 2019-03-15 2025-08-22 Novo Nordisk As Process for spray drying a glp-1 peptide
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
EP4221690A4 (en) 2020-09-29 2024-10-30 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS
JP7793626B2 (ja) * 2020-12-11 2026-01-05 メルク・シャープ・アンド・ドーム・エルエルシー 医薬品を隔離、処理、および包装するための小型封じ込めシステム
US20240315996A1 (en) 2021-02-02 2024-09-26 DuPont Nutrition USA, Inc. An aqueous gel composition comprising an ethylcellulose
KR102631642B1 (ko) * 2021-04-19 2024-02-01 주식회사 그랩실 스프레이 건조 시스템 및 스프레이 건조 방법
JP2024520798A (ja) * 2021-06-09 2024-05-24 ロンザ・ベンド・インコーポレーテッド 非晶質固体分散体の調製のための噴霧乾燥のための混合溶媒
EP4479062A4 (en) * 2022-02-18 2026-03-04 Viking Therapeutics Inc ORAL DOSAGE FORMS OF THE TR? AGONIST, VK2809, FOR THE TREATMENT OF LIVER DISORDERS, AND METHODS FOR PREPARING THESE
JP2025512788A (ja) 2022-03-25 2025-04-22 シェンチェン ファーマシン シーオー．，エルティーディー． Ｐｒｏｔａｃ化合物の医薬組成物及びその使用
WO2024011185A1 (en) * 2022-07-07 2024-01-11 Serán BioScience, LLC Methods and systems for use of low-volatility solvents for spray drying
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US20240181412A1 (en) * 2022-12-02 2024-06-06 Serán BioScience, LLC Methods and systems for spray drying temperature sensitive products
CN121311467A (zh) 2023-06-09 2026-01-09 辉瑞大药厂 N-(甲氧羰基)-3-甲基-l-缬氨酰基-(4r)-n-{(1s)-1-氰基-2-[(3s)-2-氧代吡咯烷-3-基]乙基}-4-(三氟甲基)-l-脯氨酰胺及其溶剂化物的固体形式
WO2026013055A1 (en) 2024-07-09 2026-01-15 Hovione Farmaciência S.A., Methods and systems for preparing feed solutions for spray drying

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL46210C (pt) * 1936-06-19
DE818197C (de) 1950-02-14 1951-10-22 Otto H Dr-Ing E H Hartmann Zweidruckkesselanlage fuer Hochdrucklokomotiven
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
DE2201111A1 (de) 1971-01-19 1972-07-27 Niro Atomizer As Zerstaeubungstrocknungsvorrichtung zur Herstellung von Pulver,z.B. Milchpulver
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4056599A (en) * 1975-10-20 1977-11-01 Bechtel International Corporation Process for the recovery of magnesium chloride hydrate and potassium chloride from carnallite and bischofite
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
IT1230095B (it) 1989-04-27 1991-10-05 Parenta Srl Procedimento per la preparazione di forme sterili di polveri iniettabili di antibiotici.
US5000947A (en) 1989-05-30 1991-03-19 Moleculon, Inc. Shaped articles containing liquefiable powders for delivery of cosmetic and other personal care agents
PT96229B (pt) * 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
DK0492007T3 (da) 1990-11-29 1995-06-26 Faulding F H & Co Ltd Fremgangsmåde til fremstilling af væskepåfyldte pulvere
KR0159947B1 (ko) * 1991-03-12 1998-11-16 마사아키 오카와라 분수형 가압 2류체 노즐 장치와 그것을 편입하여 이루어지는 스프레이 드라이어 장치, 및 가압 2류체에 있어서의 액적 경 제어법
DE4244466C2 (de) * 1992-12-24 1995-02-23 Pharmatech Gmbh Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19542442A1 (de) * 1995-11-14 1997-05-15 Wacker Chemie Gmbh Verfahren zur Herstellung von in Wasser redispergierbaren, Organosiliciumverbindungen enthaltenden Pulverzusammensetzungen
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627419A1 (de) 1996-07-08 1998-01-15 Bayer Ag Cycloalkano-pyridine
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19704243A1 (de) 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19832159A1 (de) 1997-09-18 1999-03-25 Bayer Ag Substituierte Tetrahydro-naphthaline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741400A1 (de) 1997-09-19 1999-03-25 Bayer Ag Benzyl-biphenyle
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6605624B1 (en) 1998-02-13 2003-08-12 Pharmacia Corporation Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
RU2144040C1 (ru) * 1998-04-07 2000-01-10 Всероссийский научно-исследовательский и технологический институт биологической промышленности Способ получения натриевой соли сукцината хитозана
US6609102B2 (en) 1998-07-20 2003-08-19 Usa Technologies, Inc. Universal interactive advertizing and payment system for public access electronic commerce and business related products and services
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CA2345108A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
JP3924124B2 (ja) 1998-09-25 2007-06-06 ファルマシア・コーポレーション コレステロールエステル輸送タンパク質活性阻害に有効な置換された多環アリールおよびヘテロアリール第三級ヘテロアルキルアミン
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
WO2000074835A1 (en) * 1999-06-08 2000-12-14 Niro A/S A process and a plant for spray drying
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1186347A1 (de) * 2000-09-05 2002-03-13 F. Hoffmann-La Roche Ag Verfahren und Vorrichtung zum Zerstäuben von Flüssigkeiten
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1469830A2 (en) * 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.

Also Published As

Publication number Publication date
EP1653928A2 (en) 2006-05-10
NZ544892A (en) 2008-09-26
AR045188A1 (es) 2005-10-19
JP2011016821A (ja) 2011-01-27
EP2283822A2 (en) 2011-02-16
TWI290852B (en) 2007-12-11
NO20060305L (no) 2006-05-03
EP2283822A3 (en) 2012-06-13
EP1653928B1 (en) 2012-03-07
IL173130A0 (en) 2006-06-11
AU2004261061A1 (en) 2005-02-10
RU2318495C2 (ru) 2008-03-10
CL2004001884A1 (es) 2005-06-03
JP2007501219A (ja) 2007-01-25
KR20060087501A (ko) 2006-08-02
US20050031692A1 (en) 2005-02-10
ATE548027T1 (de) 2012-03-15
CA2534129A1 (en) 2005-02-10
RU2006103256A (ru) 2006-06-27
MXPA06001418A (es) 2006-05-15
WO2005011636A2 (en) 2005-02-10
US10383941B2 (en) 2019-08-20
PT1653928E (pt) 2012-04-13
WO2005011636A3 (en) 2005-03-31
TW200524675A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
WO2005011636A3 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
SG170087A1 (en) Pharmaceutical compositions
NZ740615A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
EP4353221A3 (en) Novel orally administrable formulation
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
AR035348A1 (es) Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
HUP0400264A2 (hu) Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
BR0007985A (pt) Processo para a preparação de derivados multiplamente reticulados do ácido hialurÈnico (ha), ha multiplamente reticulado, ha reticulado em um ou mais polìmeros diferentes de ha, ha reticulado em um segundo polìmero, produto, e, uso de um derivado de ha multiplamente reticulado
BRPI0509039A (pt) composições de biopolìmeros e produtos dos mesmos
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
ATE424187T1 (de) Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
BR0110287A (pt) Artigos de dosagem sólida e de liberação controlada, processo para a compressão direta de artigos de dosagem sólida, mistura diretamente compressìvel, e, processo para formar a mesma
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
NZ594618A (en) Transdermal pharmaceutical preparations
BRPI0411413A (pt) composições para revestimento entérico de um produto natural e de microcápsulas com revestimento entérico contendo lectina
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
EP2178547A4 (en) PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD
BR0307344A (pt) Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
WO2025010259A3 (en) Deuterated organic compounds and uses thereof
RU2012157328A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
MX2024008371A (es) Compuestos organicos deuterados y usos de los mismos
AR041891A1 (es) Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.